Research & Development

  

Clinical Trials


Bristol-Myers Squibb is committed to providing timely, accurate and meaningful information about clinical trials it initiates and the results it obtains.

Bristol-Myers Squibb's Disclosure commitment statement is available from our US-based website.

Links to clinical trial disclosure sites:

  • ACTR.org
    • This site hosts the Australian Clinical Trials Registry, which is being established at the NHMRC Clinical Trials Centre, University of Sydney, with funding from the Australian Government, through a National Health and Medical Research Council (NHMRC) Enabling Grant.
  • ClinicalTrials.gov
    • This US-based site provides regularly updated information about federally and privately supported clinical research in human volunteers.
  • ClinicalStudyResults.org
    • This site provides a central, widely accessible,US web-based repository for clinical study results in a reader-friendly, standardised format.
  • IFPMA.org
    • The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) provides a single global source for comprehensive information on on-going or results of completed trials.

The Bristol-Myers Squibb Research and Development (R&D) organisation is one of the world's most innovative, productive, and respected scientific research organisations.

Its purpose is: to discover and develop innovative, cost-effective medicines that address significant unmet medical needs and enhance and extend human life.

In less than four years, R&D has delivered eight new drugs. By industry standards, this places Bristol-Myers Squibb among the most productive pharmaceutical companies in the world today. New products include treatments for several major disease areas, including cancer, psychiatric disorders, HIV/AIDS, hepatitis B, and rheumatoid arthritis.

In addition, our research and development activities - centered in four major U.S. facilities and numerous other facilities in the U.S. and worldwide, including Australia - are creating and sustaining an outstanding pipeline. Compounds with exciting potential are progressing through discovery, exploratory development, and full development expeditiously. With an intense focus on areas of significant unmet medical need, we are working to discover treatments specifically for:

search Institute (P
  • cancer
  • atherosclerosis/thrombosis
  • diabetes
  • obesity
  • psychiatric disorders
  • Alzheimer’s disease
  • hepatitis
  • HIV/AIDS
  • rheumatoid arthritis
  • and solid organ transplant rejection.